BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has expanded its antibody-drug conjugate (ADC) collaboration agreement with Genentech, Inc., a member of the Roche Group (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY). Under the expanded agreement, Genentech will pay an upfront fee of $12 million for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech.
